AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association for Cancer Research®

POSTER LISTING

PROFFERED PRESENTATIONS
POSTER SESSION A
POSTER SESSION B

Current as of February 9, 2026

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association for Cancer Research®
2509022F

Proffered Presentations

PR001, A002 Exploiting HIF-driven endogenous retroviral neoantigens to advance kidney cancer immunotherapy. Qinqin Jiang, Dana-Farber Cancer Institute, Boston, Massachusetts.

PR002, A016 Design of dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy to treat advanced renal cell carcinoma (RCC). Yufei Wang, Dana-Farber Cancer Institute, Boston, Massachusetts.

PR003, A022 Ferritin-dependent iron storage and ferritinophagy impact ferroptosis resistance in chromophobe renal cell carcinoma. Wafaa Bzeih, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PR004, A027 Lipid auxotrophy underlies ferroptosis sensitivity in clear cell renal cell carcinoma. Ji-Young Kim, Memorial Sloan Kettering Cancer Center, New York City, New York.

PR005, A008 APOE-mediated immune-metabolic reprogramming of macrophages drives lipid delivery to tumor cells in clear-cell renal cell carcinoma. Tien Hsu, China Medical University Yingcai Campus, Taichung City, Taiwan.

PR006 Evidence for the involvement of HIF-2α biology in the clinical efficacy of casdatifan, a novel HIF-2α inhibitor, in clear cell renal cell carcinoma (ccRCC). Jonathan Yingling, Arcus Biosciences Inc, Hayward, California.

PR007, A032 Chronic cGAS activation drives immunosuppressive remodeling and resistance to antiangiogenic tyrosine kinase inhibitors in ccRCC. Hongchao He, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PR008, A012 Single cell transcriptomic investigation of tumor-infiltrating CD8+ T cells in renal cell carcinoma (RCC) resistant to immune checkpoint inhibition (ICI). Rishabh Rout, Yale University, New Haven, Connecticut.

PR009, A036 Spatial single-cell transcriptomics reveal targetable macrophage subsets associated with antiangiogenic therapy resistance in renal cell carcinoma. Xiande Liu, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PR010, B017 Deciphering the mechanistic basis of HIFα paralog target selectivity in kidney cancer. Nitin H. Shirole, Dana-Farber Cancer Institute, Boston, Massachusetts.

PR011, B001 Breakage of chromosome 3p initiates clear cell renal cell carcinoma evolution. Rashmi Dahiya, University of Texas Southwestern Medical Center, Dallas, Texas.

PR012, B006 Co-operation of vhl and pbrm1 in early ccRCC morphogenesis. Samvid Kurlekar, University of Oxford, Oxford, United Kingdom.

PR013, B012 Genetic evolution of sarcomatoid/rhabdoid de-differentiation in renal cancers. Natalie R. Abuelsamen, McGill University, Montreal, Quebec, Canada.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research

2S09022F

PR014, B013 Shared germline architecture across renal cell carcinoma, coronary artery disease, and clonal hematopoiesis implicates a regulatory haplotype at the TERT promoter. Maxine Sun, Dana-Farber Cancer Institute, Boston, Massachusetts.

PR015 Epigenetic dysfunction promotes dependence on the NF-I/A transcription factor in kidney cancer. Abhishek A. Chakraborty, Cleveland Clinic, Cleveland, Ohio.

PR016, B034 Functional loss of actin-regulatory protein Profilin1 in vascular endothelial cells promotes a T-cell supportive chemical milieu in kidney cancer in a TRIM24-dependent manner. Sudeep Kumar Maurya, University of Pittsburgh, Pittsburgh, Pennsylvania.

PR017, B026 Exploiting CDK4/6-mTORC1 dependency reveals synergistic therapeutic potential in translocation renal cell carcinoma. Shikha Gupta, Dana-Farber Cancer Institute, Boston, Massachusetts.

PR018, B022 Activity-based network analysis identifies NEK5 as a PROTAC-targetable vulnerability in ccRCC. Cheng Zhang, UT Southwestern Medical Center, Dallas, Texas.

PR019, B031 Integrative multi-omic profiling reveals immune microenvironment subtypes in renal cell carcinoma. Keith Lawson, University Health Network, Toronto, Ontario, Canada.

PR020, B029 Targeting cadherin-17 in translocation renal cell carcinoma. Prateek Khanna, Dana-Farber Cancer Institute, Boston, Massachusetts.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research®
2509022F

Poster Session A

Saturday, March 14

5:45-7:15 p.m.

A001   Mitochondrial potential as a biomarker of T cell fitness and function in cancer immunotherapy. Katy Beckermann, Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville, Tennessee.

A003   Hsp70 gene expression is enriched in lymphocytes in renal cell carcinoma patients that respond to immune checkpoint inhibitors. Ethan Burns, Yale University, New Haven, Connecticut.

A004   SRF promotes an immunopermissive microenvironment in sarcomatoid renal cell carcinoma. Thomas J. Carroll, University of Texas Southwestern Medical Center, Dallas, Texas.

A005   Biologic insights from spatial analysis of sarcomatoid renal cell carcinoma metastasis to inform therapeutic strategies. Hyeyeon Gong, University of Virginia, Charlottesville, Virginia.

A006   Tumor-specific MHC-II shapes an inflamed immune and stromal microenvironment in clear cell renal cell carcinoma. Ruchi Gupta, Yale School of Medicine, New Haven, Connecticut.

A007   Endothelial cell-mediated immune suppressive mechanism in ccRCC and the implication for effective immune check point therapy. Tien Hsu, China Medical University Yingcai Campus, Taichung City, Taiwan.

A009   Multicellular modules and tumor programs shape the tumor microenvironment and predict immune checkpoint inhibitor (ICI) response in clear cell renal cell carcinoma (ccRCC). Katsuhiro Ito, Yale University, New Haven, Connecticut.

A010   The discovery and development of a bispecific t cell engager prodrug targeting ENPP3 for renal cell carcinoma. Yu Liang, Probio, Inc., Gaithersburg, Maryland.

A011   Characterizing the structure of the immune checkpoint B7-H7 to optimize immune activation with targeted therapeutics. Kathleen M. Mahoney, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

A013   Bridging the mouse modeling gap in clear cell renal cell carcinoma bone metastasis for immunotherapy testing. Stefan Maksimovic, Florida State University, Cape Coral, Florida.

A014   Engineered neutrophils for intratumoral delivery and targeting. Anirudh Udutha, Brown University, Providence, Rhode Island.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research
2509022F

A015   Phase II trial of perioperative Lenvatinib plus Pembrolizumab in locally advanced nonmetastatic clear cell renal cell carcinoma. BaoHan T. Vo, Emory University, Decatur, Georgia.

A017   Clonally expanded CD8+ T cells exhibit tissue-specific differentiation and variable antigen specificity in renal cell carcinoma. Lena V. Wirth, Yale University, New Haven, Connecticut.

A018   A retrospective analysis of concomitant opioid usage with immunotherapy in stage IV renal cancer. Mona Yuan, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey.

A019   Engineering novel CAR NK cells to overcome TGF-β suppression in renal cell carcinoma. Fuguo Liu, Dana-Farber Cancer Institute, Boston, Massachusetts.

A020   Tumor-infiltrating lymphocytes and peritumoral tertiary lymphoid structures as biomarkers of response to first-line nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma enrolled in the COSMIC 313 trial. Mohamed Farghaly, Brigham and Women's Hospital, Boston, Massachusetts.

A021   Investigation of the impact of the HIF-2α inhibitor belzutifan on T-cell cytotoxicity in renal cell carcinoma (RCC). Soki Kashima, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.

A023   Loss of the transcription factor ATF4 reprograms glucose metabolism in clear cell renal cell carcinoma. Yuling Chi, Weill Cornell Medicine, New York, New York.

A024   Interrogating mechanisms underlying AHCYL1 dependency in kidney cancer. Noah M. Dubasik, Case Western Reserve University, Cleveland, Ohio.

A025   SLC1A1/EAAT3 sustains oncogenic metabolic programs in kidney cancer. Treg Grubb, Cleveland Clinic, Cleveland, Ohio.

A026   Uncovering genetic regulators of metabolic plasticity and ferroptosis in renal medullary carcinoma. Chelsee Holloway, National Cancer Institute, Frederick, Maryland.

A028   Patient derived organoids identify targetable metabolic adaptations in metastatic ccRCCs. Shuhei Kamada, University of Texas Southwestern Medical Center, Dallas, Texas.

A029   Structure-guided design of SLC1A1/EAAT3-selective inhibitors reveals a metabolic vulnerability in kidney cancer. Pooneh Koochaki, Cleveland Clinic Research, Cleveland, Ohio.

A030   Defining the role of ceramide metabolism in clear cell renal cell carcinoma progression. Augustine Takyi, University of Utah, Salt Lake City, Utah.

A031   Cross-platform integration of serum NMR and MRI radiomics identifies robust biomarkers for kidney cancer. Poornima Verma, Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh, India.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association for Cancer Research

A033   Peptide-mediated targeting of the CDK4 chaperone network in kidney cancer. Sara Cayaban, SUNY Upstate Medical University, Syracuse, New York.

A034   HIF-2-mediated gene expression is highest in metastatic and cluster-exclude clear cell renal cell carcinoma tumors. Scott M. Haake, Vanderbilt University Medical Center, Nashville, Tennessee.

A035   Targeting ISCA2 and Fe-S assembly to induce ferroptosis in kidney cancer. Mei Yee Koh, University of Utah, Salt Lake City, Utah.

A037   Inhibition of the HIF-2α-PTHrP axis ameliorates paraneoplastic hypercalcemia in clear cell renal cell carcinoma. Arijit Mal, University of Texas Southwestern Medical Center, Dallas, Texas.

A038   Nuvisertib (TP-3654) and Dordaviprone (ONC201) synergize to reduce renal cell carcinoma cell viability. Kimberly S. Meza, Brown University, Providence, Rhode Island.

A039   Fragmentomics-derived profiling of transcription factor binding site (TFBS) accessibility from liquid biopsies in metastatic renal cell carcinoma (mRCC). Changsu L. Park, University Health Network, Toronto, Ontario, Canada.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research

Poster Session B

Sunday, March 15

5:45-7:15 p.m.

B002   Vhl-/-Tsc1-/- mice rapidly develop clear cell renal cell carcinoma with pronounced metabolic and redox reprogramming that necessitates NRF2 signaling. Xiaoqing Cathy Cheng, Washington University in Saint Louis, Saint Louis, Missouri.

B003   Lesion distribution and prognosis of renal cell carcinoma bone metastasis: A novel evaluation model based on random survival forests. Zixiong Huang, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.

B004   Belzutifan and lenvatinib mutually reshape renal cell carcinoma tumor microenvironment through the HIF-2A axis. Douglas Linn, Merck & Co., Inc., Boston, Massachusetts.

B005   Conditional reprogramming models for translational studies in urological cancer. Xuefeng Liu, The Ohio State University, Columbus, Ohio.

B007   Leveraging HIF2α expression in the kidney epithelium to generate a genetically engineered mouse model for clear-cell renal cell carcinoma (ccRCC). Vijyendra Ramesh, Dana-Farber Cancer Institute, Boston, Massachusetts.

B008   Comprehensive pathological analysis of 1,369 renal cell carcinoma patients reveals novel biomarkers and establishes a predictive model for clinical outcomes. Chuandong Wang, Peking University First Hospital, Department of Urology, Beijing, China.

B009   Identification of key immunohistochemical biomarkers and construction of a predictive model for pulmonary metastasis in renal cell carcinoma. Chuandong Wang, Peking University First Hospital, Department of Urology, Beijing, China.

B010   VHL inhibits autophagy and tumor development by modulating ATG14 hydroxylation in a PHD1-dependent manner. Chuandong Wang, Peking University First Hospital, Department of Urology, Beijing, China.

B011   Common VHL mutations and the genotype-phenotype correlation: A retrospective study of 1172 patients with von Hippel-Lindau syndrome in China. Chuandong Wang, Peking University First Hospital, Department of Urology, Beijing, China.

B014   GPNMB:CD44 signaling drives tumor progression in translocation renal cell carcinoma. Kaushal Asrani, Johns Hopkins University, Baltimore, Maryland.

B015   Chromothripsis driven loss of NSD1 and SETD2 disrupts an epigenetic-kinase circuit governing mitotic fidelity. Ruhee Dere, Baylor College of Medicine, Houston, Texas.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research®
2509022F

B016 Establishing a combinatorial genetic screening platform to uncover cancer-specific dependencies in renal medullary carcinoma. Olga Drozdovitch, National Cancer Institute, Frederick, Maryland.

B018 Profiling the ccRCC surfaceome reveals SEMA5B as a potential therapeutic membrane target. Yanyan Hu, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts.

B019 Systemic proteomic remodeling following nephrectomy in renal cell carcinoma. Stephanie Schwartz, Yale University, New Haven, Connecticut.

B020 Survivin regulates tumorigenesis and immunogenicity of ccRCC. Shivani S. Tuli, University of Pittsburgh, Pittsburgh, Pennsylvania.

B021 CRISPRi screening reveals an enhancer-PLXNA1 axis as a critical regulator in ccRCC. Tao Wang, UT Southwestern Medical Center, Dallas, Texas.

B023 RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma. Lei Guo, Texas A&M University, Houston, Texas.

B024 A mitochondrial plasma proteomic signature identifies metastatic chromophobe RCC. Tiegang Han, Brigham and Women's Hospital, Boston, Massachusetts.

B025 Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma. Prathyusha Konda, Dana-Farber Cancer Institute, Boston, Massachusetts.

B027 UNC8209: A potent and selective TBK1 degrader for ccRCC. Chengheng Liao, University of Texas Southwestern Medical Center, Dallas, Texas.

B028 Familial CTR9 mutation reprograms Wilms Tumor cells to a blastemal state and confers vulnerability to CDK9 inhibition. Gui Ma, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin.

B030 Profilin-1 regulates mitochondrial function and tumorigenicity in chromophobe renal cell carcinoma. Kaylee M. Montanari, University of Pittsburgh, Pittsburgh, Pennsylvania.

B032 Role of FSP1 in ferroptosis resistance of chromophobe renal cell carcinoma. Steven Safi, Brigham and Women's Hospital, Boston, Massachusetts.

B033 Sarcomatoid transformation rewires the immune spatial landscape and checkpoint regulation in chromophobe renal cell carcinoma. Yan Tang, Brigham and Women's Hospital, Boston, Massachusetts.

B035 Spatial multi-omic profiling of sarcomatoid and rhabdoid renal cell carcinoma reveals spatially distinct immune and tumor cell populations. Zachary A . Yochum, Yale School of Medicine, New Haven, Connecticut.

AACR Special Conference in Cancer Research
INNOVATIONS IN KIDNEY CANCER RESEARCH
March 13-16, 2026 | Philadelphia, PA

AACR
American Association
for Cancer Research

B036   Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study. Vladislav Petkau, Sverdlovskiy Regional Oncological Dispensary, Ekaterinburg, Russian Federation.

B037   Gut microbial metabolism shapes renal cell carcinoma growth. Vaani A. Nanavaty, Cleveland Clinic, Cleveland, Ohio.

B038   TFE3 fusion oncoprotein condensate as a mechanism in translocation renal cell carcinoma. Choon Leng So, Johns Hopkins University, Baltimore, Maryland.

B039   Urine liquid biopsy for kidney cancer: High-volume cfRNA extraction enhances detection of renal cancer biomarkers for early detection. Nafiseh Jafari, nRichDX, Irvine, California.